Skip to main content

Table 2 Characteristics of the 21 studies included in meta-analysis

From: Comparison of the efficacy of hematopoietic stem cell mobilization regimens: a systematic review and network meta-analysis of preclinical studies

Study Mice characteristics Experimental arm Dose
Abraham et al. [51] C57BL/6, Female, 7–8 weeks Long-term SD G-CSF; AMD3100; T-140; long-term SD G-CSF + T-140; long-term SD G-CSF + AMD3100 G-CSF, 2.5 μg/mouse s.c. twice daily for 4 days; AMD3100 5 mg/kg s.c. 2 h before harvest; T-140 5 mg/kg s.c. 2 h before harvest
Kubonishi et al. [56] C57BL/6, male and female, 7–12 weeks SCA; long-term SD G-CSF; long-term SD G-CSF + SCA G-CSF, 125 μg/kg s.c. twice daily for 4 days; SCA, 100 mg/kg i.v. 30 min before harvest
di Giacomo et al. [72] C57BL/6 EP80031; long-term SD G-CSF + EP80031; AMD3100 + EP80031; long-term SD G-CSF + AMD3100; long-term SD G-CSF + AMD3100 + EP80031 EP80031, 15 mg/kg i.v. 1 h before harvest; G-CSF, 2.5 μg/mouse s.c. twice daily for 4 days; AMD1300, 5 mg/kg s.c. 1 h before harvest
Lucas et al. [74] C57BL/6, male, 8 weeks Long-term SD G-CSF; long-term SD G-CSF + desipramine; AMD3100; AMD3100 + desipramine; long-term SD G-CSF + reboxetine G-CSF, 125 μg/kg s.c. twice daily for 4 days; AMD 3100, 5 mg/kg s.c. 1 h before collection; desipramine, 10 mg/kg/day i.p. for 8 days; reboxetine, 5 mg/kg/day i.p. for 8 days
Hoggatt et al. [77] C57BL/6 Meloxicam; indomethacin; long-term LD G-CSF; AMD3100; long-term LD G-CSF + indomethacin; long-term LD G-CSF + meloxicam; AMD3100 + meloxicam G-CSF, 50 μg/kg s.c. twice daily for 4 days; AMD 3100, 5 mg/kg i.p. 1 h before collection; meloxicam, 0.5–12 mg/kg s.c. for 4 days; indomethacin, 0.5–2.5 mg/kg s.c. twice daily for 4 days; AH23848, 10 μg per mouse i.p. for 4 days; L-161,982, 10 μg per mouse i.p. for 4 days
Karpova et al. [78] C57BL/6 POL5551; HD POL5551; AMD3100 POL5551, 5 or 100 (HD) mg/kg i.p. 2 or 4 h before harvest; AMD3100, 5 mg/kg i.p. 1 h before harvest.
Chen et al. [81] C57BL/6 Long-term SD G-CSF; ML141; long-term SD G-CSF + ML141 G-CSF, 200 μg/kg/day s.c. for 5 days; ML141, 10 μg/kg/day i.p. for 5 days
Ghobadi et al. [82] C57BL/6 Bortezomib; long-term SD G-CSF; AMD3100; long-term SD G-CSF + Bortezomib; AMD3100 + Bortezomib Bortezomib, a single dose of 0.8mg/kg i.v.; G-CSF, 250 μg/kg/day s.c. for 4 days; AMD3100, 5 mg/kg s.c.
He et al. [83] C57BL/6, 8–10 weeks 10d-FLT-3L; short-term SD G-CSF + AMD3100; 10d-FLT-3L + AMD3100 FLT-3L, 350 μg/kg/day i.p. for 10 days; G-CSF, 150 μg/kg/day i.p. for 5 days; AMD3100, 5 mg/kg i.p. 1 h before harvest
Saez et al. [84] C57BL/6, male, 6–12 weeks Long-term SD G-CSF; long-term SD G-CSF + heparin; G-CSF + Anti-VCAM-1 Ab; AMD310; heparin; AMD3100 + heparin G-CSF, 125 μg/kg s.c. twice for 4 days; heparin, 100 U i.p. 1 h before harvest; Anti-VCAM-1 Ab, 2 mg/kg/day i.v. for 3 days; AMD3100, 5 mg/kg s.c. 1 h before harvest
Zhang et al. [85] C57BL/6 Me6; AMD3100; long-term SD G-CSF; long-term SD G-CSF + AMD3100; long-term SD G-CSF + Me6 Me6, 5 mg/kg s.c. 12 h before harvest; AMD3100, 5mg/kg s.c. 1 h before harvest; G-CSF, 2.5 μg per mouse s.c. twice daily for 4 days
Forristal et al. [86] C57BL/6, male, 9–12 weeks Long-term SD G-CSF; long-term SD G-CSF + AMD3100; long-term SD G-CSF + FG-4497; long-term SD G-CSF + AMD3100 + FG-4497 G-CSF, 125 μg/kg s.c. twice daily for 4 days; AMD3100, 5 mg/kg s.c. 1 h before harvest; FG-4497, 20 mg/kg/day i.p. for 3 days
Lu et al. [91] C57BL/6, male, 6–8 weeks LECT2; AMD3100; AMD3100 + LECT2 LECT2, 300 μg/kg/day s.c. for 5 days; AMD 3100, 5 mg/kg s.c. 1 h before collection
Karpova et al. [94] C57BL/6 HD POL5551; 14d-HD POL5551; 14d-HD AMD3100; 14d-ALT1188; 14d-HD POL5551 + HD AMD3100; 14d-HD POL5551 + CWHM-823 POL5551, 100mg/kg i.p. as a single dose or as continuous infusion for 2 weeks via subcutaneously implanted pumps; ALT1188, 33 mg/kg i.p. as a single injection or as continuous infusion for 2 weeks; AMD3100, 20 mg/kg i.p. as a single injection or as continuous infusion for 2 weeks; CWHM-823, 3 mg/kg i.p.
Ogle et al. [96] C57BL/6, male, 8–12 weeks VPC01091; AMD3100; AMD3100 + VPC01091 AMD3100 5mg/kg i.p. 1.5 h before harvest; VPC01091 5mg/kg i.p. 1.5 h before harvest
Adamiak et al. [104] C57BL/6, 4–6 weeks Short-term LD G-CSF; AMD3100; short-term LD G-CSF + ARL67156; AMD3100 + ARL67156; short-term LD G-CSF + AMPCP; AMD3100 + AMPCP G-CSF, 100 μg/kg/day s.c. for 3 days; AMD 3100, 5 mg/kg i.p. 1 h before collection; ARL67156, 2 mg/kg i.p.; AMPCP, 4 mg/kg i.p.
Alt et al. [105] C57BL/6, Male, 6–10 weeks Short-term SD G-CSF; AMD3100; short-term SD G-CSF + AMD3100; IL-33; short-term SD G-CSF + IL-33; AMD 3100 + IL-33; short-term SD G-CSF + AMD3100 + IL-33 G-CSF, 200 μg/kg/day s.c. for 3 days; AMD 3100, 5 mg/kg i.p. 1 h before collection; IL-33, 0.04 mg/kg/day i.p. for 3 days
Bisht et al. [106] C57BL/6, male, 8–9 weeks Short-term SD G-CSF; short-term SD G-CSF + FG-4497 G-CSF, 125 μg/kg s.c. twice daily for 2 days; FG-4497, 20 mg/kg/day i.p. for 3 days;
Liu et al. [108] C57BL/6 CASIN; AMD3100; CASIN + AMD3100 CASIN, 1.2mg/kg i.v. 2 h before harvest; AMD3100, 5mg/kg i.p. 2 h before harvest.
Müller et al. [109] C57BL/6 AMD3100; AMD3100 + LGB321 AMD3100, 5 mg/kg s.c.; LGB321, 100 mg/kg s.c.
Fang et al. [112] C57BL/6 HF51116; AMD 3100; long-term SD G-CSF; G-CSF + HF51116; long-term SD G-CSF + AMD 3100 G-CSF, 100 μg/kg every 12h s.c. for 4 days; AMD 3100, 5 mg/kg s.c.; HF51116, 5 mg/kg s.c.
  1. Abbreviations: ALT1188 a small molecule CXCR4 antagonist; AMPCP an inhibitor of cell surface ectonucleotidase CD73; ARL67156 an inhibitor of cell surface ectonucleotidase CD39; CFCs colony-forming cells; CASIN cell division control protein 42 (Cdc42) activity-specific inhibitor; CWHM-823 small molecule very late antigen 4 (VLA4) antagonist; EP80031 synthetic octo-saccharides, a heparan sulfate mimetic; FG-4497 hypoxia-inducible transcription factor prolyl hydroxylase domain enzymes inhibitor; FLT-3L fms-like tyrosine kinase-3 ligand; G-CSF granulocyte colony-stimulating factor; HD high dose; HF51116 a new CXCR4 antagonist; IL-33 interleukin 33; LD low dose; LGB321 Proviral integration site for Moloney murine leukemia virus (PIM) kinase inhibitor; LSK cells Lin Sca1+ Kit+ cells; Me6 Me6TREN, Tris[2-(dimethylamino)ethyl]amine); ML141 cell division control protein 42 (Cdc42) inhibitor; PEGLip-G-CSF pegylated liposome formulated granulocyte colony-stimulating factor; POL5551 a peptidic CXCR4 antagonist; SCA sulfated colominic acid; SD standard dose; T-140 4F-benzoyl-TN14003, a highly selective CXCR4 antagonist; VPC01091 a selective sphingosine-1-phosphate receptor 3 antagonist